We previously demonstrated that P. aeruginosa isolates that persisted in children with cystic fibrosis (CF) despite inhaled tobramycin treat
P. AERUGINOSA DEVELOP RESISTANCE TO TOBRAMYCIN THROUGH CLUMPING
Researchers in Canada and the U.S. have shown that Pseudomonas aeruginosa can become resistant to the antibiotic tobramycin by clumping into larger aggregates and producing more of a protective sugar molecule called Psl.
The team analyzed sputum samples from a small group of children with CF who received inhaled tobramycin to treat a new P. aeruginosa infection.
They used a technique called microbial identification passive clarity technique (MiPACT) to directly view the bacteria.


















